Heart Ecg Quotes

SAMPLING OF SOME OF THE MAJOR TRIAL RESULTS WITH EDTA CHELATION A 1993analysis of 19 studies of 22,765 patients receiving EDTA chelation therapy for vascular disease found measurable improvement in 87%. A study of 2,870 patients with various degrees of degenerative diseases, especially vascular disease, almost 90% of the patients showed excellent improvement. The study measured walking distance, ECG, and Doppler blood flow changes. A small, blinded, crossover study of patients with peripheral vascular disease found significant improvements in walking distance and ankle/brachial blood flow. In 30 patients with carotid artery stenosis, there was a 30% improvement in blood flow after EDTA treatment. EDTA chelation treatment was evaluated in patients with carotid and coronary disease using technetium 99 isotope techniques. Significant improvement in arterial blood flow and ejection fraction (a measure of heart pumping ability) was reported. 65 patients on the waiting list for CABG surgery for an average of 6 months were treated with EDTA chelation therapy. The symptoms in 89% (58) improved so much they were able to cancel their surgery. In the same study, of 27 patients recommended for limb amputation due to poor peripheral circulation, EDTA chelation saved 24 limbs.

Suggested Strategies for Diagnostic and Therapeutic Management of Canine Degenerative Valvular Disease ACE, Angiotensin-converting enzyme; ECG, electrocardiogram; HF, heart failure; MR, mitral valve regurgitation; MVD, mitral valve disease.

3.5 A 45-year-old woman is noted to have dizziness, pounding of the chest, and fatigue of 3 hours’ duration. On examination, she is noted to have a blood pressure (BP) of 110/70 mm Hg and heart rate of 180 bpm. She is noted on ECG to have atrial fibrillation, and a prior baseline ECG showed delta waves. The ER physician counsels the patient regarding cardioversion, but the patient declines. Which of the following is the best therapy for her condition? A. Digoxin B. Angiotensin-converting enzyme (ACE) inhibitor C. Calcium channel blocker D. Procainamide

Rachel watches Zachariah and often, quite regularly, her heart skips a beat. If you map the ECG of the heart in phase space, its strange attractor resembles a spider. When Lev tutors Rachel in the principles of complexity, he has a dream of determinism, immanence. Through chaos, he shapes her. Through it he owns her. . . . When he teaches her to love the principles of complexity and see patterns in everything, the strange attractor that is Rachel and Zachariah is not what he had in mind; it is not a phase space he ever imagined.

Blocking potassium channels is precarious—a little blockade helps prevent arrhythmia, but too much can cause a lethal brand of ventricular tachycardia known by its French name “torsades de pointes,” or twisting of the points, due to its distinct appearance on the ECG. It is a malignant arrhythmia because it can lead to sudden death. This severe downside, along with the fact that most potassium blockers profoundly slow the heart rate, makes these drugs of little use to the athlete with AF.